SEC Company Response from CollPlant Biotechnologies Ltd (CLGN) (CIK 0001631487) (CLGN) — Dec 27, 2017
CollPlant Biotechnologies Ltd (CLGN) (CIK 0001631487)
Date: Dec. 27, 2017 · CIK: 0001631487 · Accession: 0001104659-17-075223
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214188
Referenced dates: December 19, 2017
Letter
VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CollPlant Holdings Ltd. Amendment No. 3 to Registration Statement on Form F-1 Filed November 22, 2017 File No. 333-214188
Dear Mr. Buchmiller:
On behalf of CollPlant Holdings Ltd. (the “Company”), we are writing to submit the Company’s response to the comment of the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”) dated December 19, 2017, relating to the Company’s Registration Statement on Form F-1 filed with the Commission on October 21, 2016, as amended on November 22, 2017 (the “Form F-1”).
The Company is concurrently publicly filing via EDGAR its Amendment No. 4 to the Form F-1 (“Amendment No. 4”), which reflects the Company’s response to the comment received from the Staff and certain updated information.
For ease of review, we have set forth below the numbered comment of your letter and the Company’s response thereto.
Results of Operations
1. We note your disclosure that your revenues increased during the periods presented. Please provide additional detail addressing the reasons for this increase. For example, clarify how your product offerings have changed since the prior period, discuss price and/or volume changes, changes to your distribution, and any other material factors affecting your revenues.
Response: In response to the Staff’s comment, the disclosure on pages 78 and 80 has been updated to address the reasons for the increase of revenues for the three and nine month periods ended September 30, 2017 when compared to the same periods in 2016. In addition, the disclosure on page 81 has been updated to clarify the reason for the increase of revenues for the year ended December 31, 2016 when compared to the same period in 2015.
Please contact me at 212-547-5541 if you have any questions or require any additional information in connection with this letter.
Sincerely,
/s/ Gary Emmanuel
Show Raw Text
CORRESP 1 filename1.htm Boston Brussels Chicago Dallas Düsseldorf Frankfurt Houston London Los Angeles Miami Milan Munich New York Orange County Paris Rome Seoul Silicon Valley Washington, D.C. Strategic alliance with MWE China Law Offices (Shanghai) Gary Emmanuel Attorney at Law gemmanuel@mwe.com +1 212 547 5541 December 27, 2017 VIA EDGAR Tim Buchmiller U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CollPlant Holdings Ltd. Amendment No. 3 to Registration Statement on Form F-1 Filed November 22, 2017 File No. 333-214188 Dear Mr. Buchmiller: On behalf of CollPlant Holdings Ltd. (the “Company”), we are writing to submit the Company’s response to the comment of the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”) dated December 19, 2017, relating to the Company’s Registration Statement on Form F-1 filed with the Commission on October 21, 2016, as amended on November 22, 2017 (the “Form F-1”). The Company is concurrently publicly filing via EDGAR its Amendment No. 4 to the Form F-1 (“Amendment No. 4”), which reflects the Company’s response to the comment received from the Staff and certain updated information. For ease of review, we have set forth below the numbered comment of your letter and the Company’s response thereto. Results of Operations 1. We note your disclosure that your revenues increased during the periods presented. Please provide additional detail addressing the reasons for this increase. For example, clarify how your product offerings have changed since the prior period, discuss price and/or volume changes, changes to your distribution, and any other material factors affecting your revenues. Response: In response to the Staff’s comment, the disclosure on pages 78 and 80 has been updated to address the reasons for the increase of revenues for the three and nine month periods ended September 30, 2017 when compared to the same periods in 2016. In addition, the disclosure on page 81 has been updated to clarify the reason for the increase of revenues for the year ended December 31, 2016 when compared to the same period in 2015. Please contact me at 212-547-5541 if you have any questions or require any additional information in connection with this letter. Sincerely, /s/ Gary Emmanuel cc: Yehiel Tal, Chief Executive Officer Eran Rotem, Chief Financial Officer